Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Propanc Biopharma Advances PRP to Phase 1b FIH Study

Propanc Biopharma announced corporate progress and Q3 financial results for the period ending March 31, 2026. The company is advancing its lead asset, PRP, towards a Phase 1b First-In-Human (FIH) study in advanced cancer patients with solid tumors, having executed a service agreement with FyoniBio GmbH for pharmacokinetics assay validation. Additionally, Propanc established a multi-year research collaboration with the Universities of Jaén and Granada, Spain, focusing on anti-aging compounds and supporting fibrosis and cancer-related patent applications. Financially, Propanc secured an initial $2 million from a private placement agreement for up to $100 million, reporting total assets of $14.33 million and a net loss of $6.36 million for the quarter, aiming to continually support planned R&D activities.

• Clinical Development Advancement: Propanc Biopharma is advancing its lead asset, PRP, towards a Phase 1b First-In-Human (FIH) clinical study in 30-40 advanced cancer patients with solid tumors. A service agreement has been executed with FyoniBio GmbH to establish and validate a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics assay for PRP and its activated enzyme forms from human serum, which is crucial preparation for the pivotal clinical study.
• Strategic Research Collaboration: The company has initiated a multi-year Joint Research Collaboration Agreement with the Universities of Jaén and Granada, Spain. This partnership aims to evaluate a senescence-modulating (anti-aging) compound to mitigate senescence and to conduct experiments supporting recently filed patent applications related to fibrosis and cancer. This collaboration is intended to strengthen Propanc's intellectual property around proenzymes for both cancer and age-related chronic diseases.
• Financial Strengthening: Propanc secured an initial $2 million investment from a private placement agreement, which can provide up to $100 million to accelerate clinical development. As of March 31, 2026, the company reported total assets of $14.33 million, a reduction in total liabilities by $2.10 million, and convertible notes reduced to $55,000 from $538,000. Net cash from financing activities was $4.47 million, with quarter-end cash at $443,702, indicating improved financial positioning to support R&D.

Addressing Unmet Needs in Advanced Solid Tumors

Current treatment approaches for recurrent and metastatic cancer face fundamental challenges that limit therapeutic success and patient outcomes. Drug resistance emerges as a primary barrier, significantly limiting the long-term effectiveness of targeted therapeutics and often leading to treatment failure and cancer recurrence. The inherent complexity of metastatic disease, characterized by tumor heterogeneity and diverse patient-specific factors, creates additional obstacles for developing effective treatment strategies.

• Resistance mechanisms pose the greatest challenge, with cancer cells developing both inherent and acquired resistance to conventional therapeutic approaches through genetic mutations, epigenetic alterations, and tumor microenvironment adaptations that promote rapid resistance acquisition and increased metastasis

• Tumor heterogeneity creates significant treatment complexity, as metastatic cancer patients experience vastly different oncologic outcomes depending on patient- and disease-specific characteristics, making trial design challenging yet necessary for improving outcomes

• Limited curative potential remains a fundamental issue, as effective treatments for metastatic disease frequently fall short of producing a cure, with metastatic cancers traditionally considered incurable by conventional therapy

• Immunotherapy limitations include emerging immunotoxicity and autoimmunity as significant drawbacks, weak immune responses from insufficient delivery of immunomodulators, and unregulated immune system modulation leading to autoimmunity and non-specific inflammation

• Cancer-specific resistance patterns vary significantly, with particular tumor subsets showing inherent resistance to specific treatments (such as pancreatic and colorectal cancers to mda-7/IL-24) and investigators only beginning to understand differential sensitivity across cancer types

• Suboptimal survival outcomes persist despite dramatic advances, with median survival for metastatic lung cancer improving from 4.5 months to over one year, yet remaining disappointing and requiring further therapeutic improvements

PRP's Safety Profile as it Enters First-In-Human Study

Published safety and tolerability data for platelet-rich plasma (PRP) demonstrates a generally favorable profile across diverse clinical indications, with most adverse events characterized as mild and transient. Recent 2024-2025 studies across multiple conditions support this safety profile, including painless administration in oral autoimmune blistering diseases, absence of bleeding or thrombotic events in immune thrombocytopenia treatment with rilzabrutinib, and no significant adverse effects in stress urinary incontinence therapy. In vulvovaginal atrophy treatment, no adverse events were reported in breast cancer survivors treated with autologous PRP combined with hyaluronic acid, and no complications occurred in comparative studies with hyaluronic acid alone.

However, the safety profile varies by indication and administration method, with some conditions showing increased adverse event rates compared to standard treatments. In oral lichen planus, intralesional PRP demonstrated statistically significant increases in side effect frequency, particularly pain, compared to steroid treatment, along with higher disease recurrence rates during three-month follow-up. Conversely, large-scale meta-analyses in lateral epicondylitis involving 511 patients across eight randomized controlled trials reported no serious adverse effects, and arteriovenous fistula studies with PRT-201 showed adverse event rates similar to placebo groups.

The safety data reveals important considerations regarding medication interactions and long-term effects that require further investigation. Systematic reviews indicate that aspirin, acetaminophen, and nonselective NSAIDs should be suspended before PRP injection due to their potential to diminish platelet aggregation and treatment efficacy, while COX-2-selective NSAIDs and statins do not require withholding. Despite the generally positive safety profile, researchers consistently note the need for standardization of PRP preparation techniques and acknowledge that long-term safety effects remain incompletely characterized across most indications, particularly in osteoarthritis management where preparation variability contributes to outcome inconsistencies.

PRP: Beyond Cancer to Age-Related Chronic Diseases

Platelet-rich plasma (PRP) is being investigated across a diverse range of age-related chronic diseases and conditions beyond oncology. Clinical trials encompass musculoskeletal disorders, dermatological conditions, reproductive health, and other degenerative diseases. These studies employ various intervention models ranging from single-center preliminary studies to large-scale randomized controlled trials.

• Musculoskeletal conditions including knee osteoarthritis (18 RCTs with 1,995 patients), elbow epicondylitis, plantar fasciitis (20 trials with 1,268 participants), and chronic whiplash-associated disorder, with intervention models primarily using intra-articular PRP injections compared against placebo, hyaluronic acid, or corticosteroids

• Androgenetic alopecia treatment in a 2022 study of 78 patients using single-spin PRP preparation injected in affected areas for 3 monthly sessions followed by 3 bimonthly sessions, achieving successful outcomes in 71.4% of male and 73.4% of female patients

• Periodontal infrabony defects through network meta-analysis of 153 RCTs, where PRP is combined with bone graft materials (autogenous, allogeneic, xenogeneic, or alloplastic) with or without barrier membranes to improve clinical and radiographic outcomes

• Repeated implantation failure (RIF) with network meta-analysis of 16 RCTs including 2,008 participants, comparing PRP against other immunomodulatory therapies and demonstrating significantly higher live birth rates versus IU-GCSF, LMWH, and intralipid treatments

• Systemic sclerosis-related ulcers in a 2024 study of 10 patients using weekly homologous PRP gel applications for up to eight weeks, resulting in 78% reduction in ulcerated area and marked pain improvement

• Recurrent urinary tract infections through a proof-of-concept study with 63 women receiving 4 monthly intravesical PRP injections versus continuous antibiotic treatment, achieving 51.5% treatment success rate in the PRP group

Propanc Charts a Dual Course: Oncology Gene Therapy and Anti-Aging Innovation

Propanc Biopharma's recent corporate update signals a pivotal moment for the company, as it advances its lead asset, proliferin-related protein (PRP), towards a Phase 1b First-In-Human study in advanced solid tumors. This move is particularly noteworthy given that PRP is an antiangiogenic gene therapy, a strategy designed to inhibit the formation of new blood vessels essential for tumor growth. Existing research underscores the challenges of developing angiostatic proteins due to production and pharmacokinetic limitations, which gene therapy aims to circumvent by enabling sustained in vivo expression. Preclinical data for adenoviral delivery of proliferin-related protein (Ad-PRP) have demonstrated compelling efficacy, including complete tumor rejection and prolonged survival in animal models of melanoma, suggesting a high therapeutic ceiling for both localized and metastatic cancers. The initiation of a Phase 1b study represents a critical de-risking step, moving this innovative approach closer to clinical validation.

Simultaneously, Propanc is strategically diversifying its pipeline through a multi-year research collaboration focused on anti-aging compounds. This initiative is exploring the potential of Polygonatum Rhizoma polysaccharide (PRP), a natural product shown to significantly extend lifespan and improve symptoms of Alzheimer's disease in preclinical models. This dual focus on oncology and age-related diseases positions Propanc in two distinct, high-growth therapeutic areas, potentially broadening its market reach and intellectual property portfolio.

However, this ambitious strategy comes with inherent considerations. The translation of gene therapies from preclinical success to human efficacy and safety remains a significant hurdle, requiring meticulous clinical development. Furthermore, the company's reported net loss highlights the substantial capital demands of advancing multiple R&D programs, necessitating robust financial management and continued investment. Lastly, managing the intellectual property for two distinct types of assets—a complex gene therapy and a natural product-derived compound—will be crucial for establishing clear market differentiation and maximizing long-term value. Propanc's progress reflects a bold pursuit of novel therapeutic solutions, but success will hinge on navigating these scientific, financial, and strategic complexities effectively.